Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled PC786 for acute RSV infection in adult hematopoietic stem cell transplant recipients
2018-001667-24Phase 2Terminated
- Sponsor
- Pulmocide
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing PC786 inhalation with Placebo inhalation (2 arms). Primary endpoint: Primary: Slope of RSV load over Days 1–3. Started Jun 2018; status: terminated.
02
Drugs
PC786
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2018-001667-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001667-24.